J Clin Periodontol. 2022 Jul 24. doi: 10.1111/jcpe.13706. Online ahead of print.
ABSTRACT
AIM: To evaluate the efficacy of recombinant human platelet-derived growth factor-BB (rhPDGF) combined with a cross-linked collagen matrix (CCM) for the treatment of multiple adjacent gingival recession type 1 defects (MAGRs) in combination with the coronally advanced flap (CAF).
MATERIALS AND METHODS: Thirty patients were enrolled in this triple-blind, randomized, placebo-controlled, trial and treated with either CAF + CCM + rhPDGF, or CAF + CCM + saline. The primary outcomes was mean root coverage (mRC) at 6 months. Complete root coverage (CRC), gain in gingival thickness (GT), keratinized tissue width (KTW), volumetric and ultrasonographic changes and patient-reported outcome measures (PROMs) were also assessed. Mixed-modeling regression analyses were used for statistical comparisons.
RESULTS: At 6 months, the mRC of the CCM + rhPDGF and CCM alone groups were 88.25%, and 77.72% respectively (p=0.02). A significant gain in GT was consistently observed for both treatment arms, and more so for the patients receiving the matrix containing rhPDGF through time (0.51 mm vs 0.80 mm, on average, p=0.01). The rhPDGF + CCM treated patients presented greater volume gain, higher soft tissue thickness, and a superior esthetic score.
CONCLUSION: rhPDGF enhances the clinical, volumetric, and esthetic outcomes of MAGRs above the results achieved with CAF + CCM alone. (ClinicalTrials.gov NCT04462237).
PMID:35871600 | DOI:10.1111/jcpe.13706
